Ensysce Biosciences (ENSC) Stock: Buy, Sell, or Hold?
ENSC - Ensysce Biosciences, Inc. Common Stock
$0.49
-0.03 (-5.62%)
▼
5d:
+10.66%
30d:
+22.12%
90d:
+84.78%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ENSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENSC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENSC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ENSC is currently trading at $0.49, which is considered extended relative to its 30-day fair value range of $0.36 to $0.46.
Technical Outlook: Technically, ENSC is in a uptrend. Immediate support is located at $0.38, while resistance sits at $0.53. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: ENSC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+1594.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENSC is in a uptrend. Immediate support is located at $0.38, while resistance sits at $0.53. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: ENSC scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.25 (+1594.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.36 -
$0.46
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price extended above range (+5.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 1594.4% below Wall St target ($8.25)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.36 -
$0.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.38
Resistance Level
$0.53
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.74
Wall Street Target
$8.25
(+1594.4%)
Revenue Growth (YoY)
-15.1%
Profit Margin
-280.5%
Share & Embed Analysis
Last updated: September 11, 2026 10:51 PM ET
Data refreshes hourly during market hours. Next update: 11:51 PM
Data refreshes hourly during market hours. Next update: 11:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
